Health Care & Life Sciences » Biotechnology | RegeneRX Biopharmaceuticals Inc.

RegeneRX Biopharmaceuticals Inc.

RegeneRX Biopharmaceuticals Inc.
Stock Exchange Other OTC
EPS
$0.01
Market Cap
$22.34 M
Shares Outstanding
131.51 M
Public Float
63.65 M

Profile

Address
15245 Shady Grove Road
Rockville Maryland 20850
United States
Employees -
Website http://www.regenerx.com
Updated 07/08/2019
RegeneRx Biopharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development of a novel therapeutic peptide, Thymosin beta 4, or Tß4, for tissue and organ protection, repair, and regeneration. The firm evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. Its products include RGN-259, RGN-352, and RGN-137.

Financials

View All
Created with Highcharts 5.0.14RegeneRX Biopharmaceuticals Inc.Net Income. Fiscal year is January-December. All values USD Thousands.6716712 7532 7535 2705 2702292292862861 9931 99320132014201520162017201801k2k3k4k5k6k
Created with Highcharts 5.0.14RegeneRX Biopharmaceuticals Inc.Sales/Revenue. Fiscal year is January-December. All values USD Thousands.29290060609393565669692013201420152016201720180255075100

Allan L. Goldstein
Chairman & Chief Scientific Officer
J. J. Finkelstein
President, Chief Executive Officer & Director